Your browser doesn't support javascript.
loading
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio, Nicola; Granberg, Dan; Grossman, Ashley; Saletan, Stephen; Klimovsky, Judith; Panneerselvam, Ashok; Wolin, Edward M.
Afiliação
  • Fazio N; European Institute of Oncology, Milan, Italy. Electronic address: nicola.fazio@ieo.it.
  • Granberg D; Departments of Medical Sciences and Endocrine Oncology, Uppsala University, Uppsala, Sweden.
  • Grossman A; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital University of Oxford, Oxford, England.
  • Saletan S; Novartis Pharmaceuticals Corp, Florham Park, NJ.
  • Klimovsky J; Novartis Pharmaceuticals Corp, Florham Park, NJ.
  • Panneerselvam A; Novartis Pharmaceuticals Corp, Florham Park, NJ.
  • Wolin EM; Cedars-Sinai Medical Center, Los Angeles, CA.
Chest ; 143(4): 955-962, 2013 Apr.
Article em En | MEDLINE | ID: mdl-23187897
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Octreotida / Tumores Neuroendócrinos / Sirolimo / Imunossupressores / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Chest Ano de publicação: 2013 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Octreotida / Tumores Neuroendócrinos / Sirolimo / Imunossupressores / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Chest Ano de publicação: 2013 Tipo de documento: Article